Monash University has announced its partnership with US-based global clinical research organisation ClinChoice, strengthening collaboration between academia and industry to support the development of innovative therapies.
Formalised through a signed Memorandum of Understanding (MoU), the partnership establishes a three-year framework to support collaboration in clinical trials and clinical research. Under the agreement, Monash and ClinChoice will work together to originate and deliver clinical trials across early- and late-phase development, including first-in-human and global multi-regional studies. Individual projects will be progressed through separate agreements, enabling flexible collaboration across a range of therapeutic areas.
Together, Monash and ClinChoice will offer biotechnology partners an integrated pathway to impact by combining global clinical development, regulatory and data capabilities with access to one of Australia's most comprehensive clinical trial ecosystems.
Through its partnerships with leading health services, Monash forms Australia's largest clinical trial network, spanning more than 7,000 hospital beds across five major health service partners – Alfred Health, Eastern Health, Monash Health, Peninsula Health and Cabrini Health – as well as engaging more than 3,000 general practitioners. Together, this ecosystem supports approximately 25% of Australia's clinical trial activity, serving a catchment population of more than 4.5 million patients.
ClinChoice is a global clinical research organisation supporting early-stage biotechnology companies, particularly in oncology, immunology and inflammation, and cardiovascular and metabolic diseases. With more than 3000 studies completed globally over the past decade, ClinChoice has strong experience working with global biotech companies in delivering early phase (phase I, II, IIT) clinical trials, alongside pivotal stage (phase III) programs, and maintains a strong presence across US, Asia (China), Europe, and Southeast Asia.
Professor Robyn Ward AM, Deputy Vice-Chancellor (Research and Enterprise), said this partnership reflects Monash's growing role as a partner of choice for global biotechnology and pharmaceutical organisations seeking to collaborate with leading research institutions.
"This new impact-driven partnership with esteemed global partner, ClinChoice, will leverage Monash's expertise in research and healthcare innovation, from our clinical ecosystem to our deep research expertise."
"By combining our strengths with ClinChoice's global capability, we can do excellent work bringing new therapies and technologies to patients while strengthening collaboration between our talented researchers and the global biotechnology sector."
The collaboration builds on engagement facilitated through the Monash Boston Hub – a front door for biotech, pharma and industry partners seeking to collaborate with Monash University's globally recognised research ecosystem.
